AGE RELATED MACULAR DEGENERATION

This study planned to test a small telescope implant for people with severe vision loss from advanced age-related macular degeneration. The device was meant to improve central vision by magnifying images onto healthy parts of the retina. However, the study was withdrawn before en…

This early-stage trial tests a gene therapy called NG101 for wet age-related macular degeneration (wAMD), a leading cause of vision loss. About 20 adults aged 50 to 89 who still need regular eye injections will receive a one-time shot under the retina. The goal is to see if the t…

This early-phase study tests the safety of an experimental drug called RO7669330, given as an eye injection, for people with geographic atrophy (a late stage of dry age-related macular degeneration). The study involves 27 participants and will monitor for side effects and how the…

This early-stage trial tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 30 participants receive eye injections of K8 and are monitored for 26 weeks to check s…

This early-stage trial tests a gene therapy called KH658 for people with wet age-related macular degeneration (AMD). The treatment aims to deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent eye injections. Nine participants aged…

This study tests a new treatment called OpRegen, made from stem cells, for people with advanced dry age-related macular degeneration (AMD). The cells are placed under the retina to replace damaged cells and slow disease progression. The trial involves 24 adults aged 50 and older …

This study follows 18 people who already received RetinoStat, a gene therapy for wet age-related macular degeneration, to see if it remains safe over time. Researchers track side effects and vision changes. The goal is to understand long-term risks, not to test if the treatment w…

This early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for frequent eye inj…

This study tests whether a pre-filled syringe is as safe as the traditional vial when giving the medicine bevacizumab for certain eye diseases. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will receive inject…

This study tests a new, high-resolution camera that takes 3D pictures of the back of the eye. It aims to see tiny details in the retina of people with age-related macular degeneration (AMD). The goal is to help doctors diagnose AMD earlier and track the disease better. About 50 a…

This study tests a new system called AVIGA that uses eye-tracking to detect central vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the system's results with standard eye exams to see if it can reliably spot disease activity. Th…

This study follows 400 people with intermediate age-related macular degeneration (iAMD) for about 3 years. Researchers will watch how the disease advances to more severe stages and test if measuring the loss of light-sensing cells in the eye can be a useful way to track the disea…

This study looks at whether a certain type of blood vessel that grows under the retina in age-related macular degeneration (AMD) might actually help preserve vision, rather than harm it. Researchers will measure how well the retina works in areas with and without these vessels in…

This study is a 5-year extension that follows people who were in the original AREDS or AREDS2 studies. The goal is to observe how age-related macular degeneration (AMD) and cataracts naturally progress over time. About 110 participants will have yearly eye exams and occasional bl…